Last reviewed · How we verify
Elidel-Creme
Elidel (pimecrolimus) is a calcineurin inhibitor that suppresses T-cell activation and inflammatory cytokine production in the skin.
Elidel (pimecrolimus) is a calcineurin inhibitor that suppresses T-cell activation and inflammatory cytokine production in the skin. Used for Atopic dermatitis (eczema) in adults and children ≥2 years, Short-term and intermittent long-term treatment of mild to moderate atopic dermatitis.
At a glance
| Generic name | Elidel-Creme |
|---|---|
| Sponsor | Technische Universität Dresden |
| Drug class | Calcineurin inhibitor (topical immunosuppressant) |
| Target | Calcineurin; macrophilin-12 |
| Modality | Small molecule |
| Therapeutic area | Dermatology/Immunology |
| Phase | FDA-approved |
Mechanism of action
Pimecrolimus binds to macrophilin-12 and inhibits calcineurin, preventing dephosphorylation and nuclear translocation of NFAT, which blocks T-cell proliferation and release of inflammatory mediators. This localized immunosuppression reduces the inflammatory cascade characteristic of atopic dermatitis without the systemic effects of topical corticosteroids.
Approved indications
- Atopic dermatitis (eczema) in adults and children ≥2 years
- Short-term and intermittent long-term treatment of mild to moderate atopic dermatitis
Common side effects
- Application site burning or irritation
- Headache
- Nasopharyngitis
- Skin infections
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Elidel-Creme CI brief — competitive landscape report
- Elidel-Creme updates RSS · CI watch RSS
- Technische Universität Dresden portfolio CI